Jagannath, Sundar

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 4,978

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 3,061

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 2,632

An inflammatory cytokine signature predicts COVID-19 severity and survival

Del Valle, D. M., Kim-Schulze, S., Huang, H.-H., Beckmann, N. D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T. H., Madduri, D., Stock, A., et al. (2020) · Nature Medicine

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 2,605

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.

Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 1,756

Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.

Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 1,730

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood

Multiple Myeloma Research and TreatmentsStatistical Methods in Clinical Trials

Cited by 1,036

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

Lohr, J. G., Stojanov, P., Carter, S. L., Cruz-Gordillo, P., Lawrence, M. S., Auclair, D., Sougnez, C., Knoechel, B., Gould, J., Saksena, G., et al. (2014) · Cancer Cell

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 988

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

Richardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 861

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

Dispenzieri, A., Kyle, R., Merlini, G., Miguel, J. S., Ludwig, H., Hajek, R., Palumbo, A., Jagannath, S., Blade, J., Lonial, S., et al. (2009) · Leukemia

Multiple Myeloma Research and TreatmentsAmyloidosis: Diagnosis, Treatment, Outcomes

Cited by 815

Oral selinexor-dexamethasone for triple-class refractory multiple myeloma.

Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., Moreau, P., Dingli, D., Cole, C., Lonial, S., et al. (2019) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 666

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Martin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., et al. (2023) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 663

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 523

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

Richardson, P. G., Jacobus, S. J., Weller, E. A., Hassoun, H., Lonial, S., Raje, N. S., Medvedova, E., McCarthy, P. L., Libby, E. N., Voorhees, P. M., et al. (2022) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 487

Bortezomib enhances dendritic cell (DC)–mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications

Spisek, R., Charalambous, A., Mazumder, A., Vesole, D. H., Jagannath, S., & Dhodapkar, M. V. (2007) · Blood

Immunotherapy and Immune ResponsesMultiple Myeloma Research and Treatments

Cited by 388

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., et al. (2014) · Blood

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 381

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Kumar, S. K., Dimopoulos, M. A., Kastritis, E., Terpos, E., Nahi, H., Goldschmidt, H., Hillengass, J., Leleu, X., Beksac, M., Alsina, M., et al. (2017) · Leukemia

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 351

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

Cohen, A. D., Parekh, S., Santomasso, B. D., Gállego Pérez-Larraya, J., van de Donk, N. W. C. J., Arnulf, B., Mateos, M.-V., Lendvai, N., Jackson, C. C., De Braganca, K. C., et al. (2022) · Blood Cancer Journal

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 308

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Usmani, S. Z., Schjesvold, F., Oriol, A., Karlin, L., Cavo, M., Rifkin, R. M., Yimer, H. A., LeBlanc, R., Takezako, N., McCroskey, R. D., et al. (2019) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 251

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

Richardson, P. G., Weller, E., Jagannath, S., Avigan, D. E., Alsina, M., Schlossman, R. L., Mazumder, A., Munshi, N. C., Ghobrial, I. M., Doss, D., et al. (2009) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 162

IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

Lancman, G., Parsa, K., Kotlarz, K., Avery, L., Lurie, A., Lieberman-Cribbin, A., Cho, H. J., Parekh, S. S., Richard, S., Richter, J., et al. (2023) · Blood Cancer Discovery

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 140

Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients

Mazumder, A., Kaufman, J., Niesvizky, R., Lonial, S., Vesole, D., & Jagannath, S. (2008) · Leukemia

Multiple Myeloma Research and TreatmentsHematopoietic Stem Cell Transplantation

Cited by 126

CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.

Lin, Y., Martin, T. G., Usmani, S. Z., Berdeja, J. G., Jakubowiak, A. J., Agha, M. E., Cohen, A. D., Deol, A., Htut, M., Lesokhin, A. M., et al. (2023) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsCAR-T cell therapy research

Cited by 120

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

Lonial, S., Popat, R., Hulin, C., Jagannath, S., Oriol, A., Richardson, P. G., Facon, T., Weisel, K., Larsen, J. T., Minnema, M. C., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 101